Modality
mRNA
MOA
SOS1i
Target
KRASG12C
Pathway
PD-1/PD-L1
Huntington'sFTD
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ May 2030
Phase 3Current
NCT05977355
2,220 pts·Huntington's
2020-09→2030-05·Active
NCT05152548
650 pts·FTD
2017-07→TBD·Not yet recruiting
NCT07973951
2,268 pts·FTD
2025-02→2029-10·Not yet recruiting
+1 more trial
7,292 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-10-053.5y awayPh3 Readout· FTD
2030-05-274.2y awayPh3 Readout· Huntington's
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Not yet…
P3
Active
P3
Complet…
P3
Not yet…
Catalysts
Ph3 Readout
2029-10-05 · 3.5y away
FTD
Ph3 Readout
2030-05-27 · 4.2y away
Huntington's
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05977355 | Phase 3 | Huntington's | Active | 2220 | BodyWt |
| NCT05152548 | Phase 3 | FTD | Not yet recr... | 650 | PANSS |
| NCT07973951 | Phase 3 | FTD | Not yet recr... | 2268 | 6MWD |
| NCT04216486 | Phase 3 | FTD | Completed | 2154 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |